Together is a new resource for anyone affected by pediatric cancer - patients and their parents, family members, and friends.Learn More
Most children with acute lymphoblastic leukemia (ALL) are cured on current first-line therapy plans. But in 15-20 percent of cases in the United States — about 600 children — ALL comes back. When cancer returns, it is called relapse or recurrence.
As in newly diagnosed ALL, patients will undergo a medical history/physical exam, blood tests, bone marrow aspirate/ biopsy, lumbar puncture, and chest X-ray.
Relapsed childhood ALL can be a challenge to treat. Patients may require aggressive chemotherapy to attempt to achieve remission.
Medicines may include dexamethasone, vincristine, clofarabine, cyclophosphamide, etoposide, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, or vinblastine. Patients with T-cell ALL may receive nelarabine.
Patients with relapsed leukemia may be candidates for hematopoietic cell transplant (also called bone marrow transplant or stem cell transplant.)
Aggressive treatments may cause severe side effects and an increased chance of serious infections. Palliative care specialists may be involved from the beginning to assist with the management of side effects and provide additional support for patients and families. Infectious diseases specialists may be involved to work with parents to prevent infections and to treat infections if they occur.
To determine the treatment approach and prognosis, doctors consider:
Central Nervous System
Testicular (males only)
A case of ALL that relapses on therapy or less than 6 months after completion of first-line therapy has a poorer prognosis than ALL that returns more than 6 months after completion of first-line therapy.
In general, B-cell ALL has a better treatment outlook than T-cell ALL.
In addition, the care team may also look at treatment response and minimal residual disease during certain points of treatment. Minimal residual disease (MRD) predicts a poorer treatment outlook because children with detectable MRD are more likely to relapse than those in MRD-negative remission.
The risk of life-threatening infections increases dramatically during relapse for a number of reasons.
About half of children with relapsed ALL will develop a life-threatening infection. Prevention of infection can save children from developing a serious illness. Also, children who are candidates for transplant must be free of infections to have one.
Patients may be instructed to wear a mask over their nose and mouth to prevent infections.
Skin care is important. The body’s skin is an important defense against infections. When the skin breaks down, such as when a sore occurs, the body is more vulnerable to infections. Patients and families are encouraged to follow the care team’s instructions regarding good oral (inside the mouth) care and perianal (near the anus) care.
Antibiotic or antifungal medicines are often used to prevent infection in patients undergoing treatment for relapsed leukemia. These medicines can prevent many infections if taken regularly.
Families are encouraged to follow the care team’s directions in caring for the patient’s venous access catheter. It is a common site of infection.
People around the patient should wash or sanitize their hands often. Patients should not be around people who are sick.
Pain, nausea, constipation, shortness of breath, itching, anxiety, and depression can be common side effects of treatment.
To treat side effects, doctors may prescribe medications. Other treatment approaches such as integrative (complementary) medicine can be effective.
Currently 30-50% of patients survive after their first relapse. Some children may relapse more than once. Each time a patient relapses the chance of cure decreases.
Reviewed: December 2018